CCL5 and acute myeloid leukemia: Clinical observation has found that current conventional chemotherapy regimens (adriamycin combined with cytarabine) do not entirely inhibit CCL5 expression, proposing that inhibition of chemokine CCL5 expression could substantially improve the prognosis of AML (Yazdani et al., 2020).